Publications by authors named "Shiro Kurawaki"
Article Synopsis
- - A study analyzed the effectiveness of two drugs, enzalutamide and apalutamide, in treating patients with non-metastatic castration-resistant prostate cancer (nmCRPC) to understand their efficacy and adverse event (AE) profiles.
- - The research involved 191 patients, revealing that both drugs led to similar oncological outcomes, with comparable PSA response rates and no significant differences in progression-free survival (PFS) or overall survival (OS).
- - However, the side effects varied, with enzalutamide causing more fatigue and apalutamide leading to more skin rashes, indicating their differential usage may depend on AE profiles despite similar efficacy.
Article Synopsis
- A systematic review showed that a specific histological variant of upper tract urothelial carcinoma (UTUC) leads to worse outcomes compared to pure UTUC.
- This study examined 824 Japanese patients with UTUC to assess how variant histology impacts disease severity and patient survival after surgery.
- Results indicated that while variant histology was linked to worse recurrence and survival rates, its significance diminished when other factors were considered, suggesting it may not provide additional prognostic value in Japanese patients.
Article Synopsis
- * A study analyzed 895 patients who underwent nephroureterectomy for UTUC, categorizing them into two groups: those eligible for adjuvant immunotherapy and those not eligible, and evaluated their oncological outcomes through statistical models.
- * Findings indicated that the group eligible for adjuvant immunotherapy had poorer recurrence-free, cancer-specific, and overall survival rates, with pathological grades and lymphovascular invasion serving as significant risk factors for survival outcomes.
Objective: The population with pathological T3 (pT3) upper tract urothelial carcinoma (UTUC) is heterogeneous, thereby making prognostication challenging. We assessed the clinical ramifications of subclassifying pT3 UTUC after nephroureterectomy.
Methods: We conducted a retrospective analysis including 308 patients who underwent nephroureterectomy for pT3N0-1M0 UTUC.
Article Synopsis
- * Results showed that 37% of patients who had neoadjuvant chemotherapy experienced pathological downstaging, while those receiving adjuvant chemotherapy had significantly lower recurrence-free and cancer-specific survival rates.
- * The findings suggest that neoadjuvant chemotherapy may be a more effective treatment option for high-risk patients compared to adjuvant chemotherapy.